Pipeline

February 1, 2021

Company	Drug/Device	Medical Condition	Status
COVID-19 Trials and Actions
OncoSec Medical	CORVax12	COVID-19 vaccine	first patients dosed in phase 1 trial
Medigen Vaccine Biologics Dynavax	MVC-COV1901	COVID-19 vaccine	first patient dosed in phase 2 trial
VBL Therapeutics	VB-201	patients with severe COVID-19	first patient dosed in phase 2 trial
Other Trials and Actions
Organicell Regenerative Medicine	Zofin	chronic obstructive pulmonary disease	IND approved by the FDA
Passage Bio	PBFT02	frontotemporal dementia with granulin mutations	IND approved by the FDA
Teneobio	TNB-585	metastatic castrate-resistant prostate cancer	IND approved by the FDA
Cardiff Oncology	onvansertib	metastatic pancreatic ductal adenocarcinoma	IND approved by the FDA
Eucure Biopharma	YH001	advanced solid tumors	first patient enrolled in phase 1 trial in China
Eyepoint Pharmaceuticals	EYP-1901	wet age-related macular degeneration	first patient dosed in phase 1 trial
I-Mab Morphosys	TJ210/MOR210	relapsed or refractory advanced solid tumors	first patient dosed in phase 1 trial
Exelixis	XL102	inoperable locally advanced or metastatic solid tumors	initiation of phase 1 trial
Zymeworks	ZW49	heavily pretreated HER2 positive cancers	first patients enrolled in expansion cohort portion of phase 1 trial
Antios Therapeutics	ATI-2173	chronic hepatitis B virus infection	completion of phase 1b trial
BioInvent	BI-1808 monotherapy and in combination with Keytruda (pembrolizumab)	solid tumors and cutaneous T-cell lymphoma	first patient enrolled in phase I/2a trial
Medicure	long-term use of Aggrastat (tirofiban hydrochloride) injection	aneurysmal subarachnoid hemorrhage	completion of phase 1/2a trial
Ayala Pharmaceuticals	AL101	notch-activated recurrent or metastatic triple negative breast cancer	first patient dosed in phase 2 trial
Meissa Vaccines	MV-012-968, intranasal live attenuated vaccine	respiratory syncytial virus	first patients dosed in phase 2 trial
Surface Ophthalmics	SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle)	chronic dry eye disease	first patient dosed in phase 2 trial
DURECT	DUR-928	severe alcohol-associated hepatitis	first patient dosed in phase 2b trial
SFJ Pharmaceuticals PhaseBio	bentracimab	reversal of antiplatelet effects of Brilinta (ticagrelor)	first patient dosed in EU in phase 3 trial
Marinus Pharmaceuticals	IV ganaxolone	refractory status epilepticus	first patient enrolled in phase 3 trial
Prilenia Therapeutics	pridopidine	early-stage Huntington’s disease	first patient enrolled in Europe in phase 3 trial
Quantum Genomics	firibastat	treatment-resistant hypertension	initiation of phase 3 trial
Telix Pharmaceuticals	TLX250-CDx (89Zr-girentuximab), renal cancer diagnostic imaging agent	noninvasive detection of clear-cell renal cell carcinoma	first patients dosed in phase 3 trial
M6P Therapeutics	four recombinant enzyme and two gene therapy programs	lysosomal storage disorders	Rare Pediatric Disease designations granted by the FDA
M6P Therapeutics	two gene therapy programs	Gaucher disease and mucolipidosis	Orphan Drug designations granted by the FDA
Q BioMed	Uttroside-B	hepatocellular carcinoma	Orphan Drug designation granted by the FDA
Veralox Therapeutics	VLX-1005	heparin-induced thrombocytopenia	Orphan Drug designation granted by the FDA
Junshi Biosciences	toripalimab	first-line treatment of mucosal melanoma	Fast-Track designation granted by the FDA
PEDRA Technology	PEDRA Xauron Perfusion System	critical limb-threatening ischemia	Breakthrough Device designation granted by the FDA
Merck KGaA Pfizer	Bavencio (avelumab)	first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy	approved by the European Commission for expanded indication
Aurinia Pharmaceuticals	Lupkynis (voclosporin) in combination with background immunosuppressive therapy	adults with active lupus nephritis	approved by the FDA
Boston Scientific	Vercise Genus Deep Brain Stimulation System	deep-brain stimulation in patients with Parkinson's disease	approved by the FDA
Exelixis	Cabometyx (cabozantinib) in combination with Opdivo (nivolumab)	first-line treatment of advanced renal cell carcinoma	approved by the FDA
OrthoSpin	Generation 2 OrthoSpin system	external fixation system for orthopedic treatments	approved by the FDA
Recordati Rare Diseases	Carbaglu (carglumic acid) tablets 200mg	adjunctive therapy to standard of care for acute hyperammonemia due to propionic acidemia or methylmalonic acidemia in children and adults	approved by the FDA for new indication
Theranica	Nerivio therapeutic device	acute treatment of episodic or chronic migraine in people 12 years and older	approved by the FDA for expanded indication
ViiV Healthcare	Cabenuva (rilpivirine and cabotegravir)	HIV	approved by the FDA